A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults.
Front Pharmacol
; 13: 893166, 2022.
Article
in En
| MEDLINE
| ID: mdl-35784742
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
Language:
En
Journal:
Front Pharmacol
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: